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a b s t r a c t
New antivirals are required to prevent rising antimicrobial resistance from replication inhibitors. The aim
of this study was to analyse the range of emerging mutations in herpesvirus by whole genome deep
sequencing. We tested human herpesvirus 6 treatment with novel antiviral K21, where evidence indi-
cated distinct effects on virus envelope proteins. We treated BACmid cloned virus in order to analyse
mechanisms and candidate targets for resistance. Illumina based next generation sequencing technology
enabled analyses of mutations in 85 genes to depths of 10,000 per base detecting low prevalent minority
variants (<1%). After four passages in tissue culture the untreated virus accumulated mutations in
infected cells giving an emerging mixed population (45e73%) of non-synonymous SNPs in six genes
including two envelope glycoproteins. Strikingly, treatment with K21 did not accumulate the passage
mutations; instead a high frequency mutation was selected in envelope protein gQ2, part of the gH/gL
complex essential for herpesvirus infection. This introduced a stop codon encoding a truncation muta-
tion previously observed in increased virion production. There was reduced detection of the glycoprotein
complex in infected cells. This supports a novel pathway for K21 targeting virion envelopes distinct from
replication inhibition.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K21 is a recently described quaternary ammonium silane
molecule representing a new class of drug with antimicrobial and
antiviral properties. Quaternary ammonium compounds can solu-
bilise phospholipid bilayers leading to cell lysis and can affect virus
envelopes (Gong et al., 2012; Tsao et al., 1989; Tuladhar et al., 2012).
A recent clinical trial showed bacterial contact killing and reduced
bioﬁlms in inserts placed in the oral cavity for applications to dental
healthcare (Liu et al., 2016). Herpesvirus also exist in the oral cavity
and in vitro treatment with K21 showed antiviral effects with log
reductions in herpes simplex virus type 1, HSV-1, and human
herpesvirus 6A, HHV-6A (Gulve et al., 2016). The mechanism of
action was not deﬁned, although there was an effect on envelope
glycoprotein gB expression, which could be from reduced virus
cellular entry or signalling. We used HHV-6A as a model to analyse
the mechanism of action of K21 through characterisation of
potential resistance mutations utilising whole-genome deep-
sequencing technologies we developed for this virus (Tweedy et al.,
2015b, 2016).
HHV-6A is Roseolovirus betaherpesvirus, and linked with
neurological and cardiac disorders in immune suppressed or naive
patients (Gompels, 2016), including fatal infant myocarditis
(Simpson et al., 2016; Stefanski et al., 2016). Moreover, Rose-
oloviruses are unique among human herpesviruses in integrating
their genome in the human germline at the chromosomal telomere,
termed ciHHV-6A and ciHHV-6B. This affects approximately 1% of
people worldwide e upwards of 70 million people at risk of virus
reactivation in every cell, with evidence for links to cardiac disease
(Gravel et al., 2015; Kuhl et al., 2015; Tweedy et al., 2015b, 2016).
Current drug treatment for herpesviruses include acyclovir for HSV
and off licence use of valganciclovir for HHV-6A. These drug classes
affect virus DNA replication and are prone to antimicrobial resis-
tance mutations, new treatment options and methods to analyse
their efﬁcacy are required.
We previously developed methodologies using target enrich-
ment with next generation sequencing to characterise speciﬁcally
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the virus sequences separated from the human genome in order to
characterise their differences and also applicable to direct testing of
clinical materials. Combining this method with whole-genome
deep-sequencing, we were able to signiﬁcantly detected ‘minor
variants’ down to 1% in a mixture and applied this technology to
identify HHV-6A virus superinfection in patients with integrated
virus genomes showing 1e30% mixtures (Tweedy et al., 2015b,
2016). Here we applied this methodology to characterise minor
variants to provide an insight into the mechanism of drug selection
using K21, as a new drug class targeting the virus envelope.
HHV-6A strain U1102 was grown in JJhan cells and BAC cloned
HHV-6A U1102 (BAC virus) (kindly provided by Y. Mori, Kobe Uni-
versity, Japan) (Tang et al., 2010, 2011) in HSB2 cells. BAC viruses
were passaged four times as identically in the presence or absence
of K21 drug (0.13 mM) respectively, as previously described (Gulve
et al., 2016) and as below. Equivalent total infected cell DNA sam-
ples were extracted (Qiagen) then prepared for target enrichment
ampliﬁcation and deep sequencing as we described (Tweedy et al.,
2015a, 2016). Reference HHV-6A U1102 and ciHHV-6A strains
(Tweedy et al., 2016, Table 1) were simultaneously re-sequenced to
verify any identiﬁed SNPs (not shown). For the speciﬁc ampliﬁca-
tion, 36 primer pairs were used which ampliﬁed overlapping PCR
products across the complete genome, which were puriﬁed, pooled
and quantiﬁed using Qubit as described (Tweedy et al., 2015a,
2016). Next, Covaris sonicated DNA libraries were prepared, puri-
ﬁed and random PCR ampliﬁed using adaptor tags (NEBNext DNA
library kit). Tagged samples were run on an IlluminaMiSeq and raw
FASTQ ﬁles analysed after quality assessment and removal of
adaptor tags and primer sequences as described (Tweedy et al.,
2016). FASTQ reads were trimmed using Trimmomatic with qual-
ity scores applied, then assembled using Samtools and BWA-mem
by mapping to reference HHV-6A U1102 reference genome (HHV-
6 U1102 NC_001664 and updated from denovo assemblies).
Coverage and qualities were assessed, then contigs ordered with
manual adjustment using Artemis, and RATT used to transfer an-
notations from the reference genome (Otto et al., 2011). SNP calling
used both GATK UniﬁedGenotyper and SAMtools mpileup,
BCFtools, vcfutils varFilter pipeline, with quality scores >25 plus.
SNPs were deﬁned using a cut-off of minimum read depths of 10 as
described (Phelan et al., 2016; Tweedy et al., 2015b, 2016). SNP
databases were compiled and compared using Excel and custom
Python scripts. To analyse K21 treatment effects, distinct SNPs
compared between untreated and treated genomes were tabulated
(Table 1). Average genome coverages were between 2000 and
10,000 read depths with a sensitivity SNP cut-off of 1%. Duplicate
library compilations were >99% identical. Genome coverage from
K21 treated compared to untreated samples were ﬁve-fold lower
reﬂecting reduction of virus titre from the infected cells.
In the untreated BAC virus sample, therewere 12 SNPs identiﬁed
including two indels (one in the U86 IE2 repeat and one in a non-
coding region of U100 between gQ1 and 2). These represented
emerging populations with non-synonymous SNPs comprising
45%e73% of the sample compared to wild type. Six were non-
synonymous changes in coding genes for U86 IE2, structural com-
ponents U31 tegument, U33capsid, U50 capsid, and virion envelope
glycoproteins U39 envelope glycoprotein gB (Thr193:Ala) and U100
gQ2 (Ser42:Leu), with only the U50 capsid and IE2 SNPs previously
reported in other strains (Table 1). In contrast, comparisons be-
tween genomes of BAC virus treated and untreated showed the
effects of K21 did not accumulate the population of non-
synonymous variants in the BACmid population and retained the
wild type U1102 sequence except for two coding changes (Table 1).
Aside from three new non-coding/non miRNA SNPs, these were
reduced from six coding changes to only two, U86 IE2 (an indel
repeat Serine codon) and a second mutation in U100 gQ2, which
introduced a stop codon giving a truncated gQ2 (Trp186:stop).
To examine gQ expression, the passaged BAC-U1102 and K21-
BAC-U1102 viruses were lysed in lysis buffer, as described (Gulve
et al., 2016) and in Fig. 1 then incubated with monoclonal anti-
body Ag gQ1 (a gift from Y. Mori, Kobe University, Japan) which
immunoprecipitates the gH/gL/gQ1/gQ2 complex (Akkapaiboon
et al., 2004; Tang et al., 2011). The antibody-complexes were
bound using sepharose protein A, then eluted, separated on SDS-
PAGE, then blotted onto nitrocellulose membranes. The separated
Table 1
Coding and non-coding SNPs in BAC HHV-6A U1102 with and without K21 treatment.
ORFa RefSeq bp RefSeq:SNP Coding changes
Codon or (reverse complement)
BAC virus BAC virus K21 Comment, citation, strains
DR 8016 A:C 87% e End T2
DR 8080 G:GAC 86% e In ciHHV-6A 2284, 5055, 5814 KT895199.1
(Tweedy et al., 2016)
U left repeats 8561 AAC:A 100% e In HHV-6A (AJ AACAAC:A) KP257584
(Tweedy et al., 2015a)
U3 10116 A:AT e 44% Spliced, non-coding, polyA
U17 26147 A:T e 99% Spliced, non-coding
U19 28371 C:CA 52% e HHV-6A AJ, UTR
U31
tegument
45667 A:T Asn314:Ile AAC:ATC 73% e
U33
capsid
52148 A:G Tyr330:His (TAT:CAT) 54% e
U39
gB
61162 T:C Thr193:Ala (ACG:GCG) 58% e
U50 capsid 81583 G:A Ala258:Thr (GCA:ACA) 59% e In HHV-6A GS KC465951.1
U86
IE2
127092 C:CTGA Ser976:SerSer (repeats 9: 10) 45% 65% In CiHHV-6A 5055, 5814; (Tweedy et al., 2016)
U89 132303 TG:T 64% 79% Non-coding outside exon
Kpn repeat 140872 G:A 96% e
U100
gQ2
146729 C:T truncates gQ2; Trp186:stop (TGG:TGA) e 100% In 7/8 gQ2 cDNA clones (Tang et al., 2011)
U100 147793 C:T e 99% Non-coding between gQ1, gQ2
U100
gQ2
146862 G:A Ser42:Leu (TCG:TTG) 60% e Not in gQ2 in Akkapaiboon et al. (2004)
a Coding changes in bold; shaded ORFs show only coding changes with K21 treatment.
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proteins were then exposed to the same antibody, followed by
washing, incubation with anti-mouse antibody conjugate, further
washing and ﬁnal ﬁlm exposure as described (Gulve et al., 2016).
Results showed abundant gQ complex detection in the untreated
infected cells reduced to almost undetectable or degraded levels
after K21 treatment (Fig. 1).
BAC viruses were used to investigate drug selection as the
BACmid ‘clones’ the virus genome from mixtures of these cell-
associated viruses using a bacterial artiﬁcial chromosome
sequence, BAC, with plasmid derived sequences. However, the
reconstituted virus has to replicate in cell culture and studies from
another related herpesvirus, human cytomegalovirus, HCMV, show
that complex mixtures of SNPs can accumulate during selection for
efﬁcient replication in tissue culture (Murrell et al., 2016). These
included coding changes in components of the HCMV gH/gL pen-
tameric complex with UL128/130/131 proteins. HHV-6A does not
encode these components, but interestingly, the positional homo-
logues are gQ1/gQ2 in the gH/gL/gQ1/gQ2 complex which were
targeted in both the parent HHV-6A BAC virus and as second mu-
tation in the K21 treated BAC virus.
As cited above, we applied K21 to virus stocks of infected cell
preparations rather than puriﬁed cell free virions (Gulve et al.,
2016) and Fig. 1. This mimics infection in vivo and these stocks
have the highest virus titers compared to cell free virions, since the
virus is highly cell associated. However, since K21 can disrupt
membranes, most likely via its long alkyl side chains (Gulve et al.,
2016; Tsao et al., 1989; Tuladhar et al., 2012), this may affect
immature, defective or mutant virus in the infected cell preparation
greater than mature released wild type virions. Although, the
concentration of K21 used, 0.13 mM (Fig. 1), was 10 times lower than
that determined for cellular toxicity, IC60 1.35 mM for HSB2 cells,
(Gulve et al., 2016), different lipid and cholesterol compositions,
including lipid rafts in the membranes of the infected cell
compared to virus envelope (Tang et al., 2008), may affect mem-
brane ﬂuidity and sensitivity to K21. The K21 associated SNP is in
gQ2 (Table 1), affects the gQ complex stability (Fig. 1), and gQ has
been shown to interact with lipid rafts (Tang et al., 2008).
Furthermore, SNPs may accumulate in passaged infected cells, as
continual serial passage of virus-infected cells facilitates replication
of defective particles. These would not be viable with reduced ti-
ters, removing sufﬁcient helper virus required to propagate the
defective particles. This may explain the striking effects from K21
treated BAC-U1102. This virus did not accumulate the culture pas-
sage non-synonymous minor variants, with the exception of only
two coding SNPs. Onewas already present in the BAC virus, the U86
SNP a repeat in a known coding exon (reverse complement TCA
Serine insertion 9e10), which adds a further serine also present in
other strains and unlikely to account for the differences in envelope
glycoprotein expression.
There were three new SNPs identiﬁed after K21 treatment of the
BAC virus, which could indicate direct protein targets in addition to
overall possible saponic effects on the membrane. However, two of
these, U3 and U17, were outside known coding regions or func-
tional micro RNAs (Nukui et al., 2015). In contrast, the third SNPwas
a second mutation of the spliced U100 gene encoding a truncated
gQ2 glycoprotein, part of the gH/gL/gQ1/gQ2 complex. This glyco-
protein complex is essential for cellular infection, mediates cellular
fusion and gQ2 deletion disrupts infection (Tang et al., 2011). The
complex interacts with a receptor, the CD46 molecule (Hansen
et al., 2017; Jasirwan et al., 2014; Mori et al., 2003; Santoro et al.,
1999, 2003). Interestingly, this truncated gQ2 SNP has been previ-
ously described as a polymorphism in the passaged HHV-6A U1102
stocks used to derive the BACmid of strain U1102 (clone G-1) as
applied here. It was observed that 7/8 cDNAs from those virus
stocks contained this polymorphism (Tang et al., 2011). However,
our analyses of both the parental isolate HHV-6 U1102 and the
reconstituted BAC-HHV-6A U1102 did not show this SNP, at 1%
sensitivity. The passaged BAC virus reverted to wild type. However,
markedly after K21 treatment, 100% of the resultant virus stock
regained this gQ2 SNP.
The expression of gQ2 in the K21 treated virus was compared to
the untreated virus. The results showed no detection of the gQ
complex as detected by immunoprecipitation with a gQ1 speciﬁc
monoclonal antibody. This antibody immunoprecipitates the gH/
gL/gQ1/gQ2 glycoprotein complex, but is speciﬁc for gQ1 inwestern
blots. Previous experiments with these K21 treated stocks showed
overall 63% decreased virus titers, but similar expression of repli-
cation protein p41 (Gulve et al., 2016). While glycoprotein gQ was
reduced as shown here. This suggests the SNP causing truncation of
gQ2 may destabilise the gQ complex or alter its signalling. Previous
studies on this truncated gQ2 show it can form the gQ complex in
transfected cells, and maintains interaction with receptor CD46
(Tang et al., 2011). However, interestingly, studies on expression of
the truncated gQ2 in virus infected cells, also shows instability in
infected cells compared to virions (Tang et al., 2011). Possibly this
effect of enhanced stability in virions increases the potential
resistance to K21.
It was surprising that the BAC virus parent accumulated prom-
inent mutation mixtures. The original HHV-6A strains were iso-
lated on cord blood stem cells. While T leukemic cell lines JJhan or
HSB2 were used to passage reconstituted BAC virus and this may
affect SNP accumulation. Therefore, characterisation of host in-
teractions, genome integration, immune interactions, and antiviral
resistance may need to take account of the effects of possible
diverse mixed genome populations in BAC passaged virus. The BAC
virus have SNPs affecting infection similar to the effects on related
HCMV, which also accumulate mutations affecting the gH/gL
complex sensitive to cell tropism. New BACs may be required to
analyse antivirals or different culturing protocols. In HCMV BAC
virus, further conditional mutations are required to maintain the
wild type genome (Murrell et al., 2016). However, results here
Fig. 1. Effect of K21 (0.13 mM) on glycoprotein gQ expression. As HHV-6A is a highly cell
associated virus, HHV-6A infected HSB2 cells (cell associated virus and cell-free virus
in culture supernatant) were combined with uninfected cells, at a ratio of 1:5, passaged
four times in the presence of K21 or solvent control. Cells were cultured in RPMI 1640
media containing 10% FCS, 2 ng/ml of PHA and 5 pg/ml of IL-2. Two different sets of
infections were carried out in parallel, one with K21 and the other with the solvent
control. Once cytopathic effect was observed in the majority of cells (5e7 days post
infection), cells were mixed once again with uninfected HSB2 cells at a ratio of 1:5. This
step was repeated 4 times. After four infection cycles, total genomic DNA was isolated
from infected cells for the further sequencing analysis as shown in Table 1, while
protein lysates were also prepared for immunoprecipitation and immunoblotting
studies shown here. Infected cell protein lysates were prepared from K21 treated or
untreated cells and gQ complex expression analysed by immunoprecipitation and
immunoblot showing the gQ complex (approximately 80 Kd).
J.G. Tweedy et al. / Antiviral Research 146 (2017) 201e204 203
showed novel antiviral, K21 treatment did not accumulate the
passage-associated HHV-6A BAC SNPS; the K21 virus retained the
wild type reference strain except for the gQ2 truncation. It would
be of interest to test HCMV effects, to target salivary transmission of
both viruses.
Additional study of these mutations from BAC and K21 treated
virus and new clinical isolates would provide further understand-
ing of virus infection and antimicrobial mechanisms. K21, as a new
class of antiviral targeting virus envelope and infection, may have
promise in combinations with antivirals targeting replication.
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